As new RFAs are announced, this page will be updated with the relevant information.
To stay up to date on awards as they become available, you can sign up below to receive RFA notifications by email.
See currently open RFA/RFPs below the contact form.
"*" indicates required fields
CLOSED: Request for Letters of Intent: 2024 PCF Challenge Awards
IMPORTANT: Applying for a Challenge Award involves a 2-stage process. PCF requires a Letter of Intent (LOI), followed by full application submission upon our approval. See the RFA for online submission details.
The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world.
We especially encourage applications on prostate cancer disparity research that will help to define the origins of differential outcome for prostate cancer patients in men of under-represented populations, including those focusing on biology or health care access policy. We also seek applications conducting research in VA hospitals where research directly affects veterans with advanced prostate cancer.
The Letter of Intent (LOI) submission portal (https://pcf.smartsimple.com) opens Monday, February 26, 2024.
The LOI submission deadline is Monday, April 8, 2024, 3:00 pm, Eastern Daylight Time (EDT).
Please direct questions to [email protected].
CLOSED: The Prostate Cancer Foundation (PCF) and Pfizer Inc.
Improving Advanced Prostate Cancer Management in Latin America
Request for Proposals (RFP): Visiting Professorship Program
This RFP is to provide financial support to organizations to host and coordinate a two-day medical education program at the organization, to be led by two international Visiting Professors with expertise matched to the organization’s unmet educational needs surrounding the management of advanced prostate cancer, so that healthcare practitioners, researchers and patients can benefit from the knowledge and on-site presence of distinguished medical experts who might otherwise be inaccessible.
Our intent to support this first-time competitive VP Program for Latin America, reflects our commitment to improve outcomes for patients with advanced prostate cancer and to advance research, innovation, clinical expertise, and education for healthcare professionals in Latin America. For more information, view and download the RFP.
Grant application due date: April 4, 2024, 23:59 Eastern Time (New York, GMT -5)
Geographic Scope: Argentina, Brazil, Chile, Colombia, and Mexico
Clinical Area: Oncology — Genitourinary — Prostate Cancer
Target Audience: Medical oncologists should serve as Principal Investigator (PI) and Program Chair, but all other medical disciplines can be included in the Program plan, such as: radio-oncologists, allied prostate cancer healthcare providers, and urology, pathology and nuclear medicine MDs.
If you have questions regarding this RFP, please direct them in writing to Miguel Briceno ([email protected]) at with the subject line: 2024 ONC LATAM Improving Advanced Prostate Cancer Management in Latin America IME.
CLOSED: Request for Applications: 2024 PCF Young Investigator Awards
The Prostate Cancer Foundation (PCF) is pleased to announce a new round of funding for PCF Young Investigators. We especially encourage young investigators working on prostate cancer health disparities to apply.
PCF Young Investigator Awards will be three (3) years in duration and will provide $75,000 per year. The award funds may be used innovatively and flexibly to advance the career and research efforts of the awardee. This for example, includes funding “protected time” or direct costs for laboratory science. This award does not support indirect costs such as institutional overhead. Every PCF Young Investigator is required to be under the direct supervision of 1-3 mentors. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Forum, typically held in October, throughout the duration of their award.
Research proposals addressing disparities in care experienced by patients with prostate cancer may focus on implementation research in various populations (e.g. urban vs rural, racial, geographic or financial) or in drivers of care and outcome disparities that could potentially be addressed through changes in policy, advocacy or education. Applicants are encouraged to solicit and integrate advice from patients, patient support groups or advocates. Letters of support demonstrating such relationships are recommended.
The online application submission portal will go live at https://pcf.smartsimple.com on Monday, January 29, 2024.
The submission deadline for Applications is Monday, April 15, 2024, 3:00 pm, Eastern Daylight Time (EDT).
Please direct questions to [email protected].
CLOSED: Request for Applications (U.S. only): 2023 Bayer-PCF Health Equity Research Awards
IMPORTANT: Applying for a Bayer-PCF Health Equity Research Award involves a 2-stage process. A Letter of Intent (LOI) is first required, followed by full application submission upon our invitation. See RFA for details.
The Prostate Cancer Foundation (PCF) and Bayer are pleased to announce a Request for Team Science Applications for Bayer-PCF Health Equity Research Awards for novel health equity implementation research projects with the goal of reducing racial and ethnic disparities in the diagnosis and treatment of advanced prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF and Bayer seek high-risk, currently unfunded projects from academic institutions in the United States (U.S. only).
The deadline for emailing your Letter of Intent to [email protected] is Friday, May 5, 2023 at 3:00 p.m. Eastern Daylight Time (EDT).
Please direct questions to [email protected].
CLOSED: Request for Applications (U.S. only): 2023 Bayer-PCF Darolutamide Challenge Awards
The Prostate Cancer Foundation (PCF) and Bayer are pleased to announce a Request for Team Science Applications for Bayer-PCF Challenge Awards for novel investigator-initiated clinical investigations with correlative research for darolutamide in prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF and Bayer seek high-risk, currently unfunded projects from academic institutions in the United States (U.S. only).
Visit https://pcf.smartsimple.com on or after Friday, March 31, 2023, to complete the online full application form and attach the PDFs.
The deadline for full application submissions is Monday, June 5, 2023, at 3:00 p.m., Eastern Daylight Time (EDT)
Please direct questions to [email protected].
CLOSED: Request for Letters of Intent: 2023 PCF Challenge Awards
IMPORTANT: This year, applying for a PCF Challenge Award involves a 2-stage process. PCF requires a Letter of Intent (LOI), followed by full application submission upon our invitation. See RFA for details.
The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world.
We especially encourage applications on prostate cancer disparity research that will help to define the origins of differential outcome for prostate cancer patients in men of under-represented populations, including those focusing on biology or health care access policy. We also seek applications conducting research in VA hospitals where research directly affects veterans with advanced prostate cancer.
The deadline for emailing your Letter of Intent to [email protected] is Friday, March 10, 2023, 3:00pm, Eastern Daylight Time (EDT).
Please direct questions to [email protected].
CLOSED: Request for Letters of Intent: 2023 PCF Young Investigator Awards
IMPORTANT: This year, applying for a PCF Young Investigator Award involves a 2-stage process. PCF requires a Letter of Intent (LOI), followed by full application submission upon our invitation. See RFA for details.
The Prostate Cancer Foundation (PCF) is pleased to announce a request for applications for Young Investigator Awards. We especially encourage young investigators working on prostate cancer health disparities to apply.
PCF Young Investigator Awards will be three (3) years in duration and will provide $75,000 per year. The award funds may be used innovatively and flexibly to advance the career and research efforts of the awardee. This for example, includes funding “protected time” or direct costs for laboratory science. This award does not support indirect costs such as institutional overhead. Every PCF Young Investigator is required to be under the direct supervision of 1-3 mentors. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Forum, typically held in October, throughout the duration of their award.
Research proposals addressing disparities in care experienced by patients with prostate cancer may focus on implementation research in various populations (e.g. urban vs rural, racial, geographic or financial) or in drivers of care and outcome disparities that could potentially be addressed through changes in policy, advocacy or education. Applicants are encouraged to solicit and integrate advice from patients, patient support groups or advocates. Letters of support demonstrating such relationships are recommended.
View and Download (corrected) LOI Form
The deadline for emailing your LOI form to [email protected] is Friday, February 10, 2023, 3:00pm, Eastern Standard Time (EST).
Please direct questions to [email protected].
CLOSED: Request for Letters of Intent: 2022 PCF TACTICAL Awards (Therapy ACceleration To Intercept CAncer Lethality)
IMPORTANT: Applying for a PCF TACTICAL Award (Therapy ACceleration To Intercept CAncer Lethality) involves a 3-stage process. PCF requires a Letter of Intent (LOI), followed by full application submission upon our invitation. Following peer review, top applicants will undergo a Zoom-based interview. See RFA for details.
The Prostate Cancer Foundation (PCF) is pleased to announce a Request for LOIs for PCF TACTICAL Awards from qualified teams of academic scientists that will specifically address the development of 21st Century therapies for lethal forms of prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world. PCF will fund 2-3 of these three-year awards for $5 – $10 Million U.S.D. per award.
For more information, please view the brief video Chuck Ryan and Howard Soule produced to describe this funding mechanism: Watch video
The deadline for submitting the LOI form by email to [email protected] is Monday, June 20, 2022.
Please direct questions to [email protected].
CLOSED: Request for Letters of Intent: 2022 PCF Challenge Awards
IMPORTANT: This year, applying for a Challenge Award involves a 2-stage process. PCF requires a Letter of Intent (LOI), followed by full application submission upon our invitation. See RFA for details.
The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. High risk, currently unfunded projects are most desired.
Detailed instructions on completing the LOI form can be found on page 2 of the RFA.
The deadline for submitting your form by emailing it to [email protected] is
Monday, April 11, 2022.
Please direct questions to [email protected].
CLOSED: Request for Applications: 2022 PCF Young Investigator Awards
The Prostate Cancer Foundation (PCF) is pleased to announce a request for applications for Young Investigator Awards. We especially encourage young investigators working on prostate cancer health disparities to apply.
PCF Young Investigator Awards will be three (3) years in duration and will provide $75,000 per year. The award funds may be used innovatively and flexibly to advance the career and research efforts of the awardee. This for example, includes funding “protected time” or direct costs for laboratory science. This award does not support indirect costs such as institutional overhead. Every PCF Young Investigator is required to be under the direct supervision of 1-3 mentors. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Day, typically held in October, throughout the duration of their award.
PCF seeks applications from the global biomedical research community. Applicants traditionally under-represented in science and medicine are highly encouraged. We seek applications from early-career basic scientists, medical oncologists, pathologists, urologists, radiologists, radiation oncologists, public health experts, bioinformaticians, bioengineers, or professionals from any other field that could contribute to the end of prostate cancer. Applicants may be working in basic, translational, computational or clinical research and need not be trained specifically in prostate cancer research to be highly competitive. However, successful applicants should be working in an academic research environment capable of supporting transformational prostate cancer research. Access to and real-time interaction with a clinical environment and translational prostate cancer physician-scientists is highly desired.
Research proposals addressing disparities in care experienced by patients with prostate cancer may focus on implementation research in various populations (e.g. urban vs rural, racial, geographic or financial) or in biological drivers of care and outcome disparities that could potentially be addressed through changes in policy, advocacy or education. Applicants are encouraged to solicit and integrate advice from patients, patient support groups or advocates. Letters of support demonstrating such relationships are recommended.
Veterans Administration (VA) Hospital Applicants and Projects
In order to improve the health and wellness of our treasured US military veterans, applicants with Veterans Administration (VA) appointments are highly encouraged to apply. Projects that involve a VA Medical Center in their research proposal planning will be appreciated. This may include but is not limited to (1) creation of defined cohorts of prostate cancer patients annotated with the VA electronic medical record for the purpose of population science research; (2) blood, tissue or other body fluid specimens collection from VA prostate cancer patients for translational or clinical trial correlate research; (3) development of new biotechnologies for the diagnosis or treatment of prostate cancer patients within the VA healthcare system; (4) activation of novel IRB- and FDA-approved phase 1 and 2 clinical investigations; (5) unique genomic investigations of tumor or germline specimens from VA prostate cancer patients with the goal of understanding the unique mutations that might have occurred due to battlefield exposure to specific toxic materials; (6) precision medicine clinical trials matching pathogenic germline or tumor alterations to experimental or FDA-approved medications.
Visit https://pcf.smartsimple.com on or after February 4, 2022, complete the online application form and attach the required PDFs.
Application Deadline: Monday, April 25, 2022, 3:00 pm Eastern Daylight Time (EDT)
CLOSED: Request for Applications: PCF-Pfizer-Myovant Relugolix Challenge Awards
Pfizer Inc., the Prostate Cancer Foundation (PCF) and Myovant Sciences GmbH are proud to announce the PCF-Pfizer-Myovant Relugolix Challenge Awards, a competitive, peer-reviewed Independent Research grants program for investigators based in the United States.
The intent of this Request for Proposals (RFP) is to invite academic investigators to submit innovative proposals for clinical investigations with correlative research for relugolix in prostate cancer.
Monetary Range of Grant Awards:
- The target budget for each individual project grant is up to $500,000. However, individual projects requesting up to $750,000 will be considered.
- Applications will be reviewed by an expert review panel (ERP) led by PCF.
- The amount of the grant Pfizer will be prepared to fund for any project will depend upon the expert review panel’s evaluation of the proposal and costs involved, and will be stated clearly in the grant agreement.
Key Dates:
- RFP release date: June 7, 2021
- Grant Application due date: August 16, 2021. Please note the deadline is 23:59 Eastern Time (New York, GMT -5).
- Anticipated Grant Award Notification Date: October 11, 2021
- Anticipated Project Start and End Dates: December 2021 to November 2023
How to Apply:
- Please go to www.cybergrants.com/pfizer/Research and sign in. First-time users should click “Create your password”.
- In the application:
- For the question “Are you replying to a Request for Proposal as part of the Competitive Grant Program?” select ‘Yes’
- Select the following Competitive Grant Program Name: 2021 PCF-Pfizer-Myovant Relugolix Challenge Awards
- Select the following Primary Area of Interest: Oncology — Genitourinary — Prostate Cancer
- Requirements for submission:
- Complete all required sections of the online application and upload your project proposal (see Appendix) in the Proposal/Protocol field.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.
Questions:
If you have questions regarding this RFP, please direct them in writing to Dewayne Brumlow at ([email protected]) or Jennifer Smith at ([email protected]) with the subject line “2021 PCF-Pfizer-Myovant Relugolix Challenge Awards”
CLOSED: Request for LOI Applications – PCF-Pfizer Health Equity Challenge Awards
Pfizer Inc. and the Prostate Cancer Foundation (PCF) are proud to announce the PCF-Pfizer Health Equity Challenge Awards, a competitive, peer-reviewed Independent Research grants program for investigators across the globe.
The intent of this program is to support general research projects that will improve the understanding of or reduce disparities in the diagnosis, management, and outcomes of prostate cancer patients in minority and underserved communities.
Monetary Range of Grant Awards
- Expected individual grant amounts are in the range of $100K to $150K.
- Approximately $1.5 million USD are allocated to this RFP.
- Applications will be reviewed by an expert review panel (ERP) led by PCF.
- The amount of the grant Pfizer will be prepared to fund for any project will depend upon the expert review panel’s evaluation of the proposal and costs involved, and will be stated clearly in the grant agreement.
Key Dates:
- RFP release date: February 10, 2021
- Letter of Intent (LOI) due date: April 9, 2021, 11:59pm Eastern Time (New York, GMT -5).
- Anticipated LOI Notification Date: June 30, 2021
- Only accepted LOIs will be invited to submit full proposals
- Full Proposal Deadline: August 30, 2021, 11:59pm Eastern Time (New York, GMT -5).
- Anticipated Full Proposal Notification Date: November 19, 2021
How to Apply:
– Please go to www.cybergrants.com/pfizer/loi and sign in. First-time users should click “Create your password.”
– Select the following Competitive Grant Program Name: 2021 Oncology G: PCF-Pfizer Health Equity Challenge Awards
– Complete all required sections of the online application. See Appendix A for additional details.
– If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.
Questions:
If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Dewayne Brumlow ([email protected]), with the subject line: “2021 PCF-Pfizer Health Equity Challenge Awards”
Please click here to view Frequently Asked Questions regarding the Competitive Grant Program.